UK markets open in 3 hours 49 minutes
  • NIKKEI 225

    27,461.54
    +515.87 (+1.91%)
     
  • HANG SENG

    19,633.05
    +374.29 (+1.94%)
     
  • CRUDE OIL

    69.50
    +0.17 (+0.25%)
     
  • GOLD FUTURES

    1,942.10
    +1.00 (+0.05%)
     
  • DOW

    32,560.60
    +316.02 (+0.98%)
     
  • Bitcoin GBP

    23,071.44
    +266.98 (+1.17%)
     
  • CMC Crypto 200

    615.85
    +10.81 (+1.79%)
     
  • NASDAQ Composite

    11,860.11
    +184.57 (+1.58%)
     
  • UK FTSE All Share

    4,109.20
    +69.76 (+1.73%)
     

Medigene to Participate in the H.C. Wainwright Cell Therapy Virtual Conference

Medigene AG
Medigene AG

MARTINSRIED, Germany and MUNICH, Germany, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be participating in the H.C. Wainwright Cell Therapy Virtual Conference on February 28, 2023.

Members of Medigene's management team will participate in a fireside chat and will be available for virtual one-on-one meetings with registered investors.

About Medigene
Medigene AG (FSE: MDG1) is a leading immuno-oncology company dedicated to developing T-cell therapies to effectively eliminate cancer. Its end-to-end technology platform, built on multiple proprietary and exclusive product enhancement and product development technologies, allows Medigene to create best-in-class differentiated, T Cell Receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for both safety and efficacy. This platform provides product candidates for both its in-house therapeutics pipeline and partnering. For more information, please visit www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Medigene

Pamela Keck
Phone: +49 89 2000 3333 01
E-mail: investor@medigene.com

LifeSci Advisors

Sandya von der Weid
Phone: +41 78 680 05 38
E-mail: svonderweid@lifesciadvisors.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.